Xoma | XOMA - Selling And Administration Expenses

Stock Price
25.81
Daily Change
1.41 5.78%
Monthly
-5.35%
Yearly
9.74%
Q1 Forecast
25.01

Xoma reported $11M in Selling and Administration Expenses for its fiscal quarter ending in June of 2024.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Agenus USD 23.6M 448K Sep/2025
Agios Pharmaceuticals USD 42.97M 1.7M Dec/2025
Ardelyx USD 83.61M 378K Sep/2025
aTyr Pharma USD 4.8M 130K Sep/2025
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Celldex Therapeutics USD 6.63M 546K Sep/2025
Curis USD 4.79M 100K Jun/2024
Eli Lilly USD 3.13B 391.3M Dec/2025
Emergent BioSolutions USD 182.8M 82.3M Jun/2023
Incyte USD 390.41M 61.33M Dec/2025
MacroGenics USD 9.9M 600K Sep/2025
Novartis USD 3.31B 134M Sep/2025
Novartis USD 3.3B 137M Sep/2025
Pfizer USD 4.08B 894M Dec/2025
Prothena USD 13.24M 2.67M Sep/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Xoma USD 11M 2.54M Jun/2024